DOP30: Identifying dietary factors and metabolites that may promote healthier Crohn Disease microbiome and mucosal transcriptomics signals as future targets using Diet-OmicsECCO’23 Copenhagen 2023
DOP31: Gut metabolomic and compositional signatures predict response to treatment with exclusive enteral nutrition in children with active Crohn’s diseaseECCO’23 Copenhagen 2023
DOP32: Crohn’s disease stricture matrisome analysis reveals the anti-fibrotic activity of milk-fat globule-epidermal growth factor 8 (MFGE8)ECCO’23 Copenhagen 2023
DOP33: Single-cell analysis identifies pathological fibroblasts as a new therapeutic target to prevent intestinal fibrosis in Crohn’s disease.ECCO’23 Copenhagen 2023
DOP34: Human MD2 deficiency - an inborn error of immunity predisposing to early onset Inflammatory Bowel DiseaseECCO’23 Copenhagen 2023
DOP35: High-fat diet reduces gut microbiota-derived metabolite indole-acetic acid and aggravates colitisECCO’23 Copenhagen 2023
DOP36: Vedolizumab-treated IBD patients show an increased gut microbial diversity associated with a specific serum metabolic signatureECCO’23 Copenhagen 2023
DOP37: Efficacy and safety of 3 years of continuous ozanimod treatment: an interim analysis of the True North open-label extension studyECCO’23 Copenhagen 2023
DOP38: Upadacitinib Therapy Reduces Crohn’s Disease Symptoms Within the First Week of Induction TherapyECCO’23 Copenhagen 2023
DOP39: Endoscopic, histologic, and combined outcomes with reinitiation of ozanimod after temporary discontinuation: 2-year interim analysis of the True North open-label extension studyECCO’23 Copenhagen 2023
DOP40: Corticosteroid discontinuation and clinical outcomes in patients with moderately to severely active Crohn’s disease treated with upadacitinibECCO’23 Copenhagen 2023
DOP41: Achievement of corticosteroid-free clinical endpoints in subjects with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 trialECCO’23 Copenhagen 2023
DOP42: Efficacy of etrasimod on symptomatic relief in patients with ulcerative colitis: an analysis of the phase 3 ELEVATE UC 52 and ELEVATE UC 12 trialsECCO’23 Copenhagen 2023
DOP43: Extended induction in the True North OLE study: ozanimod efficacy in biologic-naive and biologic-experienced patientsECCO’23 Copenhagen 2023
DOP44: Tofacitinib versus corticosteroids for induction of remission in moderately active ulcerative colitis (ORCHID): A prospective randomized open-label pilot studyECCO’23 Copenhagen 2023
DOP45: Predicting late responders to filgotinib in patients with moderately to severely active Ulcerative Colitis: A post hoc analysis of SELECTION and SELECTIONLTEECCO’23 Copenhagen 2023
DOP46: Mucosal host-microbe interactions associate with clinical phenotypes in Inflammatory Bowel DiseaseECCO’23 Copenhagen 2023
DOP47: Gut microbiome contributes to the development of immune checkpoint inhibitor-related colitisECCO’23 Copenhagen 2023